Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin Amyloidosis
International Journal of Molecular Sciences · 04.11.2025 · 26 (21) · 10714
DOI: 10.3390/ijms262110714 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.11.2025. Verfasst von Selina J Hein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Biomarkers, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alnylam Pharmaceuticals®.
Abstract (Originalsprache)
In transthyretin cardiac amyloidosis (ATTR-CA), misfolded transthyretin accumulates in the myocardium, leading to wall thickening and interstitial fibrosis. Recently published in vitro studies revealed direct effects of transthyretin on the structure, function, and gene expression of cardiac fibroblasts. Therefore, we hypothesized that biomarkers known to modulate myocardial remodeling might be clinically valuable in ATTR-CA and may improve risk stratification in ATTR-CA. To analyze this hypothesis, we evaluated 14 fibrosis-related biomarkers (EN-RAGE, IGFBP-1, -2, -3, -4, -6, FGF-23, MMP-2, -7, -9, -13, TIMP-2, -4, and RAGE-AGE) in 125 patients using Luminex multiplex assays. The study cohort consists of 14 asymptomatic gene carriers (ATTRv-asymp), 47 symptomatic hereditary (ATTRv-CA), 43 wild-type Transthyretin amyloidosis (ATTRwt) patients, and 21 were healthy controls (ctrl). Associations of fibrotic biomarkers and clinical routine data with clinical outcomes—cardiac decompensation (DMP) and transplantation/death (HTX)—were assessed via hierarchical cluster analysis, regression, and prediction modeling. We found that ATTR-CA patients showed distinct biomarker profiles compared to controls. Several markers (e.g., MMP-7, RAGE-AGE, IGFBP-1, FGF-23, TIMP-2) were significantly associated with both endpoints. Cluster analysis identified a high-risk phenotype (Cluster 2) with worse renal function, greater myocardial thickening, and elevated NT-proBNP, hsTNT. Prediction modeling revealed IGFPB-1, -3, -4 and -6 as well as FGF-23, TIMP-2, and RAGE/AGE as the best predictive parameters for cluster assignment. Taken together, these findings confirm our hypothesis that fibrosis-related biomarkers are associated with adverse outcomes in ATTR-CM. Profibrotic mediators such as IGFBP-1, FGF-23, and TIMP-2 may, therefore, provide additional prognostic information beyond established cardiac biomarkers and may reflect underlying fibrotic remodeling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
- DZHK (German Center for Cardiovascular Research), Site Heidelberg/Mannheim, 69120 Heidelberg, Germany.
- Department of Hematology, Oncology and Rheumatology, Heidelberg University, 69120 Heidelberg, Germany.
- Department of Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), 69120 Heidelberg, Germany.
- German Cancer Consortium (DKTK) Core-Center, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Division of Molecular & Translational Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), 69120 Heidelberg, Germany.
ORCID-Profile: Selina J Hein, Fabian Aus dem Siepen, Arnt V Kristen, Stefan Schönland, Ute Hegenbart, Hugo A Katus, Norbert Frey, Jennifer Furkel, Mathias H Konstandin, Maximilian Knoll
Förderung
- Alnylam Pharmaceuticals®
Zitieren
APA
Hein, S. J., Aus dem Siepen, F., Kristen, A. V., Schönland, S., Hegenbart, U., Rein, K., Katus, H. A., Frey, N., Furkel, J., Konstandin, M. H., & Knoll, M. (2025). Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin Amyloidosis. International Journal of Molecular Sciences, 26(21), 10714. https://doi.org/10.3390/ijms262110714
Vancouver
Hein SJ, Aus dem Siepen F, Kristen AV, Schönland S, Hegenbart U, Rein K, et al. Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin Amyloidosis. International Journal of Molecular Sciences. 2025;26(21):10714. doi:10.3390/ijms262110714
BibTeX
@article{Hein2025,
author = {Hein, Selina J and Aus dem Siepen, Fabian and Kristen, Arnt V and Schönland, Stefan and Hegenbart, Ute and Rein, Katrin and Katus, Hugo A and Frey, Norbert and Furkel, Jennifer and Konstandin, Mathias H and Knoll, Maximilian},
title = {Profibrotic Biomarkers Correlate with Clinical Presentation and Outcome in Cardiac Transthyretin Amyloidosis},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {21},
pages = {10714},
doi = {10.3390/ijms262110714}
}
EUVIMED